gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Fms-related tyrosine kinase 4

PCL, VEGFR-3, Vascular Endothelial Growth Factor Receptor-3, Flt-4
This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: KDR, vascular endothelial growth factor, CAN, VEGF-C, HAD
Papers using PCL antibodies
Vitronectin and collagen I differentially regulate osteogenesis in mesenchymal stem cells.
Neves Nuno, In PLoS ONE, 2005
... PCL (MW = 110,000 Da) was purchased from Birmingham Polymers, lyophilized calf skin collagen I was from MP Biomedicals, and HA nanoparticles (10–50 ...
Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly
Ganjoo Kristen et al., In Case Reports in Oncology, 2002
... unit # sc-65442), rabbit anti-human VEGFR2 polyclonal antibody (Abcam, Cambridge, UK; unit # ab45010), and mouse anti-human VEGFR3 monoclonal antibody (Abcam; unit # ab51496) ...
Papers on PCL
Three-Layered PCL Grafts Promoted Vascular Regeneration in a Rabbit Carotid Artery Model.
Kong et al., Tianjin, China. In Macromol Biosci, Feb 2016
UNASSIGNED: In this study, a three layered poly (ε-caprolactone) (PCL) graft (tPCL) was fabricated by electrospinning PCL and electrospraying poly (ethylene oxide) (PEO), which has a thin dense inner layer, a loose middle layer, and a dense outer layer.
The properties, functions, and pathophysiology of maxi-anion channels.
Okada et al., Okazaki, Japan. In Pflugers Arch, Feb 2016
Among MACs so far studied, around 60 % (designated here as Maxi-Cl) possess, in common, the following phenotypical biophysical properties: (1) unitary conductance of 300-400 pS, (2) a linear current-voltage relationship, (3) high anion-to-cation selectivity with PCl/Pcation of >8, and (4) inactivation at positive and negative potentials over a certain level (usually ±20 mV).
Micellar delivery of dasatinib for the inhibition of pathologic cellular processes of the retinal pigment epithelium.
Lee et al., Hong Kong, Hong Kong. In Colloids Surf B Biointerfaces, Feb 2016
We successfully encapsulated dasatinib, a poorly soluble multi-targeted tyrosine kinase inhibitor which has great potential for the treatment of PVR, into nanoparticles prepared from micellation of PEG-b-PCL.
Prognostic value of vascular endothelial growth factor-C and podoplanin mRNA expression in esophageal cancer.
Nikliński et al., Białystok, Poland. In Oncol Lett, Dec 2015
UNASSIGNED: Vascular endothelial growth factor-C (VEGF-C), VEGF-D, VEGF receptor-3 (VEGFR-3) and podoplanin (PDPN) are involved in the spread of cancer.
The influence of substrate topography and biomaterial substance on skin wound healing.
Makvandi et al., Ahvāz, Iran. In Anat Cell Biol, Dec 2015
Therefore, we fabricated two matrices, electrospun polycaprolactone (PCL) nanofibers and collagen/chitosan film, and implanted them to the same rat models.
Management of regorafenib-related toxicities: a review.
Saif et al., New York City, United States. In Therap Adv Gastroenterol, Sep 2015
Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is an oral multikinase inhibitor that targets the angiogenic tumor microenvironment and oncogenic kinases including vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR1, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), RAF, KIT, RET and BRAF.
VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature.
Săftoiu et al., In Rom J Intern Med, Jul 2015
VEGF protein family currently comprises several members: VEGF (or VEGF-A), VEGF-B, VEGF-C and VEGF-D, VEGF-F, placental growth factor (PlGF), and their receptors VEGFR-1, VEGFR-2 and VEGFR-3.
Lymphangiogenic Markers and Their Impact on Nodal Metastasis and Survival in Non-Small Cell Lung Cancer--A Structured Review with Meta-Analysis.
Donnem et al., Tromsø, Norway. In Plos One, 2014
were significant prognostic markers of poor survival and high expression of VEGF-C, vascular endothelial growth factor receptor 3 (VEGFR3) and LVD was associated with lymph node metastasis in NSCLC.
Selective use of vandetanib in the treatment of thyroid cancer.
Antonelli et al., Pisa, Italy. In Drug Des Devel Ther, 2014
Vandetanib is a once-daily orally available tyrosine kinase inhibitor that works by blocking RET (REarranged during Transfection), vascular endothelial growth factor receptor (VEGFR-2, VEGFR-3), and epidermal growth factor receptor and to a lesser extent VEGFR-1, which are important targets in thyroid cancer (TC).
Morphological changes and expression of MMPs and TIMPs in rabbit degenerated lateral meniscus after PCL-transection.
Liao et al., Changsha, China. In Int J Clin Exp Med, 2014
INTRODUCTION: Whether the expression level of MMP-1, MMP-13 and TIMP-1 has association with the degeneration of lateral meniscus after posterior cruciate ligament (PCL) fracture is poorly understood.
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Matulonis et al., Boston, United States. In Lancet Oncol, 2014
BACKGROUND: Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3.
Activation of vascular endothelial growth factor receptor-3 in macrophages restrains TLR4-NF-κB signaling and protects against endotoxin shock.
Wang et al., Shanghai, China. In Immunity, 2014
The surface vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C were upregulated in macrophages.
Impaired humoral immunity and tolerance in K14-VEGFR-3-Ig mice that lack dermal lymphatic drainage.
Swartz et al., Lausanne, Switzerland. In J Immunol, 2012
K14-VEGFR-3-Ig transgenic mice lack dermal lymphatic capillaries and experience markedly depressed transport of dendritic cells from the skin to draining lymph nodes.
Tubular network formation by adriamycin-resistant MCF-7 breast cancer cells is closely linked to MMP-9 and VEGFR-2/VEGFR-3 over-expressions.
Hatmi et al., Paris, France. In Eur J Pharmacol, 2012
results demonstrate that the proteolytic enzyme MMP-9 promotes resistant epithelial breast cancer cells migration and tubular network formation through VEGFR-2/ VEGFR-3 activation
Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling.
Adams et al., Münster, Germany. In Nature, 2012
results establish that VEGFR2 and VEGFR3 are regulated in a highly differential manner by Notch; successful anti-angiogenic targeting of these receptors and their ligands will strongly depend on the status of endothelial Notch signalling
Possible genetic predisposition to lymphedema after breast cancer.
Hayes et al., Brisbane, Australia. In Lymphat Res Biol, 2012
Single nucleotide polymorphisms in VEGFR3 gene is associated with lymphedema after breast cancer.
VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium.
Stacker et al., Melbourne, Australia. In Cancer Cell, 2012
Our data suggest a control point for cancer metastasis within the collecting lymphatic endothelium, which links VEGF-D/VEGFR-2/VEGFR-3 and the prostaglandin pathways.
Expression of VEGF-C/VEGFR-3 in human laryngeal squamous cell carcinomas and its significance for lymphatic metastasis.
Ju et al., Yangzhou, China. In Asian Pac J Cancer Prev, 2011
High VEGFR-3 gene expression is associated with lymphatic metastasis in laryngeal squamous cell carcinomas.
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Rodríguez-Antona et al., Alcorcón, Spain. In Lancet Oncol, 2011
We assessed RECIST response, progression-free survival (PFS), overall survival, and toxicity of sunitinib with 16 key polymorphisms in nine genes: VEGFR2 (rs2305948 and rs1870377), VEGFR3 (rs307826, rs448012, and rs307821), PDGFR-α (rs35597368), VEGF-A (rs2010963, rs699947, and rs1570360), IL8 (rs1126647), CYP3A4 (rs2740574), CYP3A5 (rs776746), ABCB1 (rs1045642, rs1128503, and rs2032582), and ABCB2 (rs2231142).
share on facebooktweetadd +1mail to friends